HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
DGAP-Media / 14.01.2022 / 14:45
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Schönefeld, 13th January 2022 - With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.
HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), has now added a high-end PCR point-of-care device to its portfolio. This device can perform a reliable RT (real-time)-PCR analysis within 45 minutes. HAEMATO already supplies numerous pharmacies, clinics and laboratories, thus reducing the workload of these facilities.
RT-PCR testing is the so-called gold standard among corona tests. The polymerase chain reaction (PCR) can be used to reliably detect pathogens in a sample from the respiratory tract mucous membranes. As the RT-PCR devices offered by HAEMATO can be used on site (point-of-care), the long way from taking the sample to the analysing laboratory is saved. The entire process is thus considerably shortened and thus accelerated.
"In addition to our day-to-day business of supplying medicines, we are currently working non-stop to supply pharmacies, clinics, laboratories and public institutions with RT-PCR devices, rapid antigen tests and FFP2 masks," says Patrick Brenske, CEO of HAEMATO AG. Attila Strauss, Managing Director of HAEMATO PHARM GmbH added: "We recognised the potential overload in healthcare at an early stage and with the addition of the PCR Point-of-Care devices to our product portfolio, we are now in a position to make an important contribution to the battle against the Corona pandemic."
The PCR Point-of-Care devices as well as standard rapid antigen tests and FFP2 masks are available for order and immediate delivery via the website www.schnelltest-antigen.de.
About HAEMATO:
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced special pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology, and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at www.haemato.de.
Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]
End of Media Release
Issuer: HAEMATO AG
Key word(s): Enterprise
14.01.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
HAEMATO AG |
|
Lilienthalstraße 5c |
|
12529 Schönefeld |
|
Germany |
Phone: |
+49 (0)30 897 30 86 70 |
Fax: |
+49 (0)30 897 30 86 79 |
E-mail: |
[email protected] |
Internet: |
www.haemato.ag |
ISIN: |
DE000A289VV1 |
WKN: |
A289VV |
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: |
1269035 |
1269035 14.01.2022
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
289,86 |
274,12 |
197,84 |
238,33 |
285,04 |
248,14 |
282,00 |
EBITDA1,2 |
11,27 |
9,96 |
1,90 |
3,31 |
12,64 |
9,66 |
12,40 |
EBITDA-Marge3 |
3,89 |
3,63 |
0,96 |
1,39 |
4,43 |
3,89 |
|
EBIT1,4 |
9,42 |
8,50 |
-18,68 |
1,63 |
11,16 |
8,30 |
11,40 |
EBIT-Marge5 |
3,25 |
3,10 |
-9,44 |
0,68 |
3,92 |
3,35 |
4,04 |
Jahresüberschuss1 |
6,98 |
6,28 |
-1,17 |
-4,83 |
6,53 |
8,19 |
6,90 |
Netto-Marge6 |
2,41 |
2,29 |
-0,59 |
-2,03 |
2,29 |
3,30 |
2,45 |
Cashflow1,7 |
-8,35 |
0,56 |
-2,76 |
14,67 |
14,05 |
19,73 |
0,00 |
Ergebnis je Aktie8 |
3,20 |
2,70 |
-0,50 |
-1,02 |
1,35 |
1,57 |
1,34 |
Dividende8 |
3,00 |
1,00 |
0,00 |
0,00 |
1,10 |
1,20 |
3,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Harry Haseloff
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Haemato |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A289VV |
15,800 |
- |
82,62 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
9,88 |
15,46 |
0,61 |
7,95 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,58 |
4,19 |
0,33 |
6,37 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,20 |
0,70 |
4,43 |
18.07.2023 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
31.05.2023 |
31.08.2023 |
16.11.2023 |
17.05.2023 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-22,35% |
-27,98% |
-40,60% |
-10,73% |
|
|